Congressional trading
Who in Congress traded BMY?
Bristol-Myers Squibb Company Common Stock · classified as Health care. 13 disclosed transactions across 8 members.
13
Transactions
8
Members
3 / 10
Buys / sells
2
Filed late
Committee overlap
3 of 8 members who traded BMY sit on a committee with jurisdiction over Health care. This is a disclosed structural overlap, not evidence of wrongdoing. Nothing here asserts that any member acted on non-public information. Jurisdiction is mapped from published House and Senate committee rules — see the methodology.
Members
5 transactions- Sell2025-12-18$1,001 - $15,000(Joint)disclosed after 18dfiling
- Partial sell2025-11-13$1,001 - $15,000(Joint)disclosed after 22dfiling
- Partial sell2025-08-14$1,001 - $15,000(Joint)disclosed after 19dfiling
- Sell2025-04-01$1,001 - $15,000(Joint)disclosed after 35dfiling
- Buy2025-01-15$1,001 - $15,000(Joint)disclosed after 23dfiling
2 transactionsCommittee overlap
1 transaction- Sell2026-05-07$15,001 - $50,000(Spouse)disclosed after 34dfiling
1 transactionCommittee overlap1 filed past the 45-day deadline- Buy2026-03-27$1,001 - $15,000disclosed after 116dfiling
1 transaction- Sell2025-06-24$1,001 - $15,000disclosed after 7dfiling
1 transactionCommittee overlap- Sell2025-03-27$1,001 - $15,000(Joint)disclosed after 8dfiling
1 transaction1 filed past the 45-day deadline- Buy2024-10-29$1,001 - $15,000(Spouse)disclosed after 317dfiling
1 transaction- Sell2024-01-09$1,001 - $15,000disclosed after 3dfiling
Where this comes from
10 transactions from House Clerk Periodic Transaction Reports and 3 from Senate eFD filings. Amounts are the statutory brackets filers report — Congress does not disclose exact values. Senate filings carry one filing date per report rather than per transaction, so “disclosed after” for a Senate row is measured to the date the whole report was filed. This page is a conflict-of-interest disclosure, not investment advice or a trading signal.